Carlos L. Arteaga

Has grant

University of Texas Southwestern Medical Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Oncogene signaling and therapeutic resistance to antiestrogens in breast cancer

Open Date: 2024-10-01

Close Date: 2025-09-30

Grant: Close

Combinations of Anti-HER2 Therapies to Eliminate Drug Resistance

Open Date: 2012-07-01

Close Date: 2017-06-30

Grant: Close

HER2 (ErbB2) gene mutations and therapeutic resistance to HER2 inhibitors

Open Date: 2007-07-01

Close Date: 2012-06-30

Articles (31)

Purpose: Activating mutations in AKT genes are rare but play an important role in the commonly dysregulated PI3K/AKT/mTOR signaling pathway in multiple cancers. NCI-MATCH (EAY131) is a tumor-agnostic platform trial that enrolled patients to targeted therapies based on matching tumor genomic alterations. Subprotocol Z1K evaluated ipatasertib, a pan-AKT inhibitor, in patients with AKT1 E17K -mutant metastatic tumors. Patients and Methods: Patients received ipatasertib 400 mg orally once daily in a 28-day cycle until progression or unacceptable toxicity. Patients with well-controlled diabetes were eligible. Patients with known KRAS , NRAS , HRAS , or BRAF mutations were excluded. Prior PI3K and mTOR inhibitors were allowed. Prior AKT inhibitors were excluded. The primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival, 6-month progression-free survival, and toxicity. Results: Thirty-five patients were enrolled, and 29 patients were included in the prespecified primary efficacy analysis. Multiple histologies were enrolled, with breast ( n = 18) and gynecologic ( n = 7) being the most common. The majority had >3 lines of prior therapy (19/29; 65.5%). The ORR was 24.1% (7/29; 90% confidence interval, 11.9%–40.6%) with P n = 25), nausea ( n = 13), and hyperglycemia ( n = 9). Grade 3/4 toxicities observed were consistent with reported toxicities for AKT inhibition. Twelve grade 3 events occurred that were thought to be at least possibly related to treatment. Conclusions: The study met its primary endpoint with an ORR of 24.1% ( P AKT1 E17K mutations. See related commentary by Dahmer Tiecher and Schram, p. 4863

Year:

2025

The MYC oncogene is frequently amplified in triple-negative breast cancer (TNBC). Here, we show that MYC suppression induces immune-related hallmark gene set expression and tumor-infiltrating T cells in MYC-hyperactivated TNBCs. Mechanistically, MYC repressed stimulator of interferon genes (STING) expression via direct binding to the STING1 enhancer region, resulting in downregulation of the T-cell chemokines CCL5, CXCL10, and CXCL11. In primary and metastatic TNBC cohorts, tumors with high MYC expression or activity exhibited low STING expression. Using a CRISPR-mediated enhancer perturbation approach, we demonstrated that MYC-driven immune evasion is mediated by STING repression. STING repression induced resistance to PD-L1 blockade in mouse models of TNBC. Finally, a small-molecule inhibitor of MYC combined with PD-L1 blockade elicited a durable response in immune-cold TNBC with high MYC expression, suggesting a strategy to restore PD-L1 inhibitor sensitivity in MYC-overexpressing TNBC.

Year:

2025

Supplementary Figure 9. Difference in baseline maximum VAF for detected somatic alterations. Panel (a) shows the maximum VAF according to the response category in patients with evaluable disease in the overall cohort. Panel (b) shows further stratification according to the treatment subprotocol.

Year:

2025

Purpose: Liquid biopsies with circulating tumor DNA (ctDNA) analysis are increasingly being utilized as a noninvasive approach to identify actionable genomic alterations in advanced/metastatic cancers. In this study, we report the correlation between ctDNA analysis of plasma samples collected from patients enrolled in the NCI-MATCH trial and tumor tissue–based sequencing. Experimental Design: We analyzed plasma samples collected from patients enrolled on 16 subprotocols of NCI-MATCH who had plasma samples collected within 90 days before starting treatment. Concordance was defined as the detection of the same gene alteration leading to patient enrollment in NCI-MATCH in both tissue and plasma. Results: We included 300 patients who were enrolled in NCI-MATCH. Most patients (81%, n = 243) were enrolled based on central tissue testing and had contemporaneous tissue and plasma samples. The tissue alteration of interest was detected in the plasma of 81.1% ( n = 197) of patients. Lower rates of detection of the tissue alteration of interest were observed in samples from 57 patients who were enrolled based on outside designated laboratory testing (56.1%, n = 32) and had noncontemporaneous tissue and plasma samples. Variations in concordance rates were observed with different alteration types, by maximum plasma variant allele frequency, and based on tumor biopsy site. Conclusions: The tumor tissue alteration of interest was detected in the plasma of 81% of patients who were enrolled in the NCI-MATCH trial based on central tissue testing and had contemporaneous tissue and plasma samples. This suggests a potential role for liquid biopsy in patient enrollment in trials evaluating biomarker-driven anticancer therapies. See related commentary by Russo et al., p. 4217

Year:

2025

Supplementary Table 9. Distribution of different genetic alterations according to response groups in different treatment arms. Shown in the table is the number of patients with molecular alteration in each response category.

Year:

2025

Supplementary Figure 8. Genomic alterations detected in patients treated in subprotocol Z1A enrolling patients with NRAS mutations who received treatment with binimetinib. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).

Year:

2025

Supplementary Figure 5. Genomic alterations detected in patients treated in subprotocol Q enrolling patients with HER2 amplifications who received treatment with ado-trastuzumab emtansine. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).

Year:

2025

Supplementary Figure 6. Genomic alterations detected in patients treated in subprotocol S1 enrolling patients with NF1 mutations who received treatment with trametinib. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).

Year:

2025

Supplementary Figure 2. Summary of genomic landscape in patients enrolled based on outside laboratory testing who had discordant mutations. Patients are stratified according to the site of tissue biopsy (primary or metastatic site). Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).

Year:

2025

Supplementary Figure 7. Genetic alterations detected in patients treated in subprotocol W enrolling patients with FGFR pathway alterations who received treatment with AZD4547. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Collaborators (51)

Lawrence Rubinstein

Statistician

National Cancer Institute

UNITED STATES
View details

Yu Wang

Staff Scientist

Vanderbilt University Medical Center

UNITED STATES
View details

Joonbeom Bae

Korea University

SOUTH KOREA
View details

Alice Chen

Head, Early Clinical Trial Development Program

National Cancer Institute

UNITED STATES
View details

housheng hansen he

Senior Scientist

-

CANADA
View details

Zhao Wang

Associate Professor (Tenured)

Baylor College of Medicine

UNITED STATES
View details

Ariella Hanker

Associate Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Ping Mu

Associate Professor

Yale University

UNITED STATES
View details

Xiaoling Li

ARS

Yale University

UNITED STATES
View details

Mark A. Dickson

-

UNITED STATES
View details

Cheryl Lewis

Associate Professor

University of Texas Southwestern

UNITED STATES
View details

Todd Aguilera

University of Texas Southwestern Medical Center

UNITED STATES
View details

Yang-Xin Fu

professor

Tsinghua University

CHINA
View details

Su Deng

Assistant Professor

Yale University

UNITED STATES
View details

Jeon Lee

Assistant Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Lisa McShane

Associate Director, Division of Cancer Treatment & Diagnosis

National Cancer Institute

UNITED STATES
View details

Angela DeMichele

University of Pennsylvania

UNITED STATES
View details

Jeremy Force

Duke University

UNITED STATES
View details

Justin M. Balko

Vanderbilt University Medical Center

UNITED STATES
View details

Hong Zhu

-

UNITED STATES
View details

Elad Sharon

Associate Professor

Harvard University

UNITED STATES
View details

Arnaldo Marin Valdés

profesor/a

Universidad de Chile

View details

brian lehmann

Research Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Benjamin Brown

Assistant Professor

Vanderbilt University

UNITED STATES
View details

Bret Mobley

Associate Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Chang-Ching Lin

Assistant Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Robert Gray

Dana-Farber Cancer Institute

UNITED STATES
View details

Kevin Kalinsky

Emory University

UNITED STATES
View details

Yuan Yuan

Scripps Research Institute

UNITED STATES
View details

Erica M. Stringer-Reasor

Associate Professor

The University of Alabama

UNITED STATES
View details

Abdullah Al Mamun

Assistant Professor

Meharry Medical College

UNITED STATES
View details

Ben Ho Park

Vanderbilt University Medical Center

UNITED STATES
View details

Petros Grivas

University of Washington

UNITED STATES
View details

Ganesh Raj

Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Guanghui Zhu

Assoicate professor

Sichuan University

CHINA
View details

QI LIU

Vanderbilt University Medical Center

UNITED STATES
View details

Anthony Davis

Assistant Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Jens Meiler

Vanderbilt University

UNITED STATES
View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Felix Y. Feng

University of California

UNITED STATES
View details

Han Liang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

kyung-min lee

Assistant professor

Hanyang University

SOUTH KOREA
View details

Rolf A. Brekken

University of Texas Southwestern Medical Center

UNITED STATES
View details

Ying Yuan

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Yitao Tang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Mohamed Gouda

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

ZHIJIAN CHEN

Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Katherine Marcelain

Associate Professor

Universidad de Chile

View details

Yan Peng

University of Texas Southwestern Medical Center

UNITED STATES
View details

Tao Wang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Yunguan Wang

Assistant Professor

Cincinnati Children's Hospital Medical Center

UNITED STATES
View details